SecBot SecBot

SPRB

SPRUCE BIOSCIENCES, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001683553 Biotech & Drug Discovery
$43.99 −1.16 (−2.57%)
Oct 26 4:00 PM ET · prev $45.15
Market cap
$132.2M
Micro cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
$144.00
+227% · range $104.00–230.00
Next earnings
Nov 9
in 14 days · EPS est. −$5.51
1 year
−64.2%
from $123.02 · Oct 27
30 days
−7.4%
from $47.51
52-week range
$38.98–127.00
−65% from high · low Oct 14
Avg volume 20D
77.6K
shares / day
Short interest
431.5K
≈15.0% of shares · +3.7%
Days to cover
4.5
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 9, 2026
Strongest NEUTRAL Spruce Biosciences reported Q2 2026 net loss of $16.2M ($6.68/share) vs $2.1M loss ($3.50/share) in Q2 2025…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 10 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$5.962 → −$5.510 over 90 days. 2 up, 5 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.7% to 431.5K shares. 4.5 days to cover, ≈15.0% of shares.

  • TrendDOWNTREND

    13% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED187,836$10.1M
MILLENNIUM MANAGEMENT LLCADD160,981$8.7M
Alyeska Investment Group, L.P.ADD81,671$4.4M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED70,548$3.8M
CITADEL ADVISORS LLCTRIM51,905$2.8M
STATE STREET CORPDOUBLED50,450$2.7M
GOLDMAN SACHS GROUP INCDOUBLED32,348$1.7M
UBS Group AGDOUBLED23,381$1.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy5Buy9Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +227%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 24, 2026Citizens
REITERATE
REITERATEMarket Outperform
Sep 17, 2026Lake Street
INITIATE
INITIATEBuy
Aug 17, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Aug 13, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Jul 13, 2026B. Riley Securities
INITIATE
INITIATEBuy
Jun 16, 2026Guggenheim
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 27, 2026
Quartel Adrian W
Chief Medical Officer
AWARD13,000 sh
Jun 30, 2026
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER
AWARD$1.2K
May 21, 2026
SPIEGELMAN DANIEL K
Director
AWARD1,700 sh
May 21, 2026
GREY MICHAEL G
Executive Chairman
AWARD1,700 sh
May 21, 2026
Barretto-Ko Percival
Director
AWARD1,700 sh
May 21, 2026
SIMPSON CAMILLA V
Director
AWARD1,700 sh
May 21, 2026
Walbert Keli
Director
AWARD1,700 sh
Mar 9, 2026
Hooks Corwin Dale
Chief Commercial Officer
AWARD11,000 sh

Earnings setup

Estimates
Nov 9
reports in 14 days
−$5.51
EPS estimate, this quarter
+8%
estimate change, 90 days
2↑ 5↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$5.51-$6.92–-$4.24+3.2%$0.00
Next Q-$5.10-$6.91–-$1.62+8.9%$0.00
Current FY-$25.32-$32.69–-$16.26+4.9%$0.00
Next FY$4.97-$19.26–$38.23-39.1%$78.7M

Short side

FINRA· Sep 30, 2026
431,541
shares short
+3.7%
vs prior settlement
4.5
days to cover
≈15.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 12, 2026 SEC
Spruce Biosciences reported Q2 2026 net loss of $16.2M ($6.68/share) vs $2.1M loss ($3.50/share) in Q2 2025, with no…
8-K — Impact 6/10
Aug 12, 2026 Earnings calendar
SPRB Q2 2026 Earnings After Market Close — 2026-08-12
Jul 27, 2026 Insider
Quartel Adrian W was granted 13,000 shares
Chief Medical Officer
Jun 30, 2026 Insider
Szwarcberg Javier B. was granted 266 shares
CHIEF EXECUTIVE OFFICER @ $4.53 ($1.2K)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
187,836 shares ($10.1M)
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — ADD
160,981 shares ($8.7M)
May 21, 2026 Insider
SPIEGELMAN DANIEL K was granted 1,700 shares
Director
May 13, 2026 SEC
Spruce Biosciences reported Q1 2026 net loss of $12.3M ($(8.94)/share), missing consensus EPS of $(7.32) by 22%. Cash…
8-K — Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
SPRB Q3 2026 Earnings After Market Close — 2026-11-09
Recent
Aug 12, 2026
Earnings date
SPRB Q2 2026 Earnings After Market Close — 2026-08-12
May 13, 2026
Earnings date
SPRB Q1 2026 Earnings After Market Close — 2026-05-13
May 11, 2026
Earnings date
SPRB Q1 2026 Earnings After Market Close — 2026-05-11
May 4, 2026
Earnings date
SPRB Q1 2026 Earnings After Market Close — 2026-05-04
Apr 17, 2026
Short interest
FTD: SPRB — 8,379 shares ($0.6M) failed to deliver
Settlement: 20260417, Price: $67.90, FTD Value: $568,934.1, SPRUCE BIOSCIENCES INC

SecBot reports

5 filings · 0 bullish · 0 bearish · 2 mixed · 3 neutral
All SPRB filing & press-release reports (5)